Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight
Cathie Wood expands ARK Invest's stake in PacBio amid a down year. PacBio's Vega sequencer offers affordable and precise genome sequencing. Non-GAAP operating expenses decreased significantly, indicating financial tightening. ARK's confidence suggests long-term potential for genomics, despite market headwinds. Biotech market grew 29% this year, but PacBio's share struggles continue.
View signal analysis